named programs · 4 · from sources
What they call their work
Joint MAP Testing Study
Collaborative research initiative to develop and validate diagnostic testing methods for MAP infection in humans
MAP Conference Series
Organizes scientific conferences to bring together researchers and clinicians to discuss the latest findings on MAP, including annual meetings in Philadelphia and Berkeley
MAP Research Funding Program
Provides grants to support scientific research on Mycobacterium avium subspecies paratuberculosis (MAP) and its potential role in Crohn's disease and other immune conditions
The MAP Gap Newsletter
Quarterly publication providing updates on MAP research, clinical findings, and foundation activities to researchers, clinicians, and patients
activities · 2 groups
What they do
-
Inflammatory Bowel Disease Research and Support 2 activities
- Conducting and promoting research on MAP in human diseaseConducts and promotes scientific research into the potential role of Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn’s disease and other conditions, including publishing findings, issuing calls for research proposals, and reporting detection rates in patient populations.
- Providing educational information on inflammatory and autoimmune diseasesProvides public information on the causes, symptoms, treatment options, and clinical course of ulcerative colitis, sarcoidosis, and type 1 diabetes, including details on immune mechanisms, genetic factors, and management strategies.
-
-
Uncategorized 1 activity
- Funding MAP sequencing researchFunds research on Mycobacterium avium subspecies paratuberculosis (MAP) through grants, including supporting Otakaro Pathways' sequencing research.
-
financials · form 990EZ · fy2025
revenue
Total revenue$15K
Contributions & grants$15K100%
Program service revenue——
Investment income——
Other revenue—
expenses
Total expenses$22K
Program expenses—
Admin / overhead—
Fundraising—
Salaries & benefits—
Grants paid out—
balance sheet
Total assets$33K
Cash—
Investments—
Liabilities—
Net assets$33K
4 years on record · 2021–2025 · YoY revenue +46.3%
leadership · form 990 part vii · fy2025
Who runs it
board members · 2
- ILDIKO MEHES — Trustee
- SHARON COONEY — Trustee
relationships · 7
Who they work with
- Johne’s Disease Information Center Partner — Collaborates by providing detailed information and resources on Johne's disease, referenced as a key source by the foundation.
- Otakaro Pathways Partner — Leads global hMAP testing with an innovative diagnostic test; referenced as a key lab in hMAP detection.
- Otakaro Pathways Partner — Receives funding from Human Para for sequencing research on MAP.
- Paratuberculosis Awareness and Research Association Partner — Provides up-to-date information and research on paratuberculosis, cited as a resource by the foundation.
- RedHill Biopharma Partner — Collaborated on the clinical development and trial of RHB-104 for multiple sclerosis.
- RedHill Biopharma Partner — Conducts clinical trials on AMAT therapy for Crohn's disease and multiple sclerosis, referenced as part of ongoing research efforts.
- University of Central Florida Partner — Hosts Prof. Saleh Naser's research which successfully cultured MAP from Crohn’s disease patients.
strategies · 4
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Combination Therapy Targeting MAP and Immune Modulationmethodology: combination_therapy_targeting_mapBy investigating combination therapies that target both Mycobacterium avium subspecies paratuberculosis (MAP) and immune dysfunction, the organization aims to improve clinical outcomes in diseases like MS, because dual-pathway intervention addresses both potential infectious etiology and the resulting immune dysregulation.
- Immune-Mediated Disease Model with Environmental Triggersmethodology: immune-mediated_disease_modelBy studying chronic immune diseases like sarcoidosis, type 1 diabetes, and ulcerative colitis as conditions arising from genetic susceptibility combined with environmental triggers such as infection, the organization identifies modifiable causal factors, because this model enables prevention and intervention strategies that go beyond symptom management to address root causes.
- MAP Causality Hypothesis-Driven Researchmethodology: etiologic_research_hypothesisBy investigating the hypothesis that Mycobacterium avium subspecies paratuberculosis (MAP) infection is a causative factor in Crohn’s disease and other immune-mediated conditions, the organization advances understanding and treatment development, because establishing etiology enables targeted interventions and redirects clinical focus toward infectious triggers in chronic immune diseases.
- Mechanistic and Molecular Detection Innovationmethodology: molecular_detectionBy using PCR-based DNA testing to detect cell-wall deficient MAP in humans, the organization improves diagnostic accuracy and research validity, because traditional methods fail to identify MAP due to its atypical microbiological characteristics, and molecular detection enables more reliable investigation of its role in disease.